Want to see DE:BAYN full AI Analyst Report?
Top Page
Bayer
(XETRA:BAYN)
Select Model
Select Model
Rating:54Neutral
Price Target:
€54.00
▲(31.39% Upside)
Action:Reiterated
Date:07/03/26
The score is held back primarily by weak financial performance (net losses, declining revenue, and leverage) despite positive cash generation. Technicals are supportive due to a strong uptrend versus moving averages, but overbought signals add near-term risk. Valuation is aided by an unusually high dividend yield, though the negative P/E underscores ongoing profitability concerns.
Positive Factors
Diversified business model (Pharma + Crop Science)
Bayer’s dual focus on pharmaceuticals and crop science provides durable revenue diversification across healthcare and agriculture. This reduces cyclicality, offers multiple long-term growth vectors (drugs, seeds/traits, crop protection, digital farming), and supports strategic resource allocation across different regulatory and demand cycles.
Negative Factors
Multi-year net losses / negative returns to shareholders
Repeated net losses and negative returns to shareholders reduce retained earnings and limit the company's ability to self-fund growth or sustain distributions. Persistent losses can force reliance on cash reserves or new financing, constrain strategic optionality, and raise the bar to restore consistent profitability over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model (Pharma + Crop Science)
Bayer’s dual focus on pharmaceuticals and crop science provides durable revenue diversification across healthcare and agriculture. This reduces cyclicality, offers multiple long-term growth vectors (drugs, seeds/traits, crop protection, digital farming), and supports strategic resource allocation across different regulatory and demand cycles.
Read all positive factors
Bayer (BAYN) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€49.24B
Dividend Yield0.31%
Average Volume (3M)2.24M
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth-2.87%
EPS Growth33.72%
CountryDE
Employees91,694
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-2.19
Shares Outstanding982,424,100
10 Day Avg. Volume2,239,372
30 Day Avg. Volume2,240,598
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.40
Price to Sales (P/S)0.80
P/FCF Ratio17.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€53.94Price Target Upside31.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)4.39
Revenue Forecast (FY)€45.66B
Bayer Business Overview & Revenue Model
Company Description
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consum...
How the Company Makes Money
Bayer makes money mainly by selling products and related services across its two operating divisions.
1) Pharmaceuticals revenue model:
- Prescription drug sales: The core revenue stream is the sale of patented and off-patent prescription medicin...
Bayer Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
46
Neutral
Cash Flow
52
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 45.24B | 45.58B | 46.61B | 47.64B | 50.74B | 44.08B |
| Gross Profit | 26.84B | 26.98B | 25.34B | 27.89B | 30.87B | 27.27B |
| EBITDA | 3.51B | 2.65B | 3.67B | 4.05B | 10.29B | 7.02B |
| Net Income | -2.16B | -3.62B | -2.55B | -2.94B | 4.15B | 1.00B |
Balance Sheet | ||||||
| Total Assets | 107.94B | 110.61B | 110.85B | 116.26B | 124.88B | 120.24B |
| Cash, Cash Equivalents and Short-Term Investments | 6.66B | 7.86B | 8.09B | 10.59B | 10.15B | 7.74B |
| Total Debt | 38.89B | 37.44B | 40.74B | 44.79B | 41.65B | 39.53B |
| Total Liabilities | 78.98B | 84.54B | 78.81B | 83.18B | 85.95B | 87.07B |
| Stockholders Equity | 28.84B | 25.95B | 31.91B | 32.93B | 38.77B | 33.02B |
Cash Flow | ||||||
| Free Cash Flow | 2.01B | 2.08B | 4.59B | 2.37B | 4.14B | 2.48B |
| Operating Cash Flow | 4.52B | 4.57B | 7.37B | 5.12B | 7.09B | 5.09B |
| Investing Cash Flow | -1.32B | -1.61B | 164.00M | -4.01B | -2.38B | 855.00M |
| Financing Cash Flow | -1.32B | -2.19B | -7.18B | -679.00M | -4.22B | -5.64B |
Bayer Technical Analysis
Positive
41.10
Price Trends
40.23
Positive
39.98
Positive
37.23
Positive
Market Momentum
3.60
Negative
67.74
Neutral
55.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BAYN, the sentiment is Positive. The current price of 41.1 is below the 20-day moving average (MA) of 44.90, above the 50-day MA of 40.23, and above the 200-day MA of 37.23, indicating a bullish trend. The MACD of 3.60 indicates Negative momentum. The RSI at 67.74 is Neutral, neither overbought nor oversold. The STOCH value of 55.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:BAYN.
Bayer Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €16.86B | 25.70 | 7.77% | 1.08% | 0.02% | 4.88% | |
66 Neutral | €2.74B | 22.50 | 6.69% | 1.50% | -0.06% | -38.81% | |
62 Neutral | €42.44B | 24.16 | 5.24% | 5.16% | -11.46% | 137.39% | |
60 Neutral | €1.45B | 43.42 | 4.19% | 0.20% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | €49.24B | -22.89 | -7.52% | 0.31% | -2.87% | 33.72% |
* General Sector Average
DE:BAYN
Bayer
50.12
22.69
82.71%
DE:BAS
BASF SE
47.55
6.54
15.94%
DE:BEI
Beiersdorf
77.82
-29.71
-27.63%
DE:AFX
Carl Zeiss Meditec
30.60
-19.91
-39.42%
DE:COP
CompuGroup Medical
27.45
3.96
16.88%
Bayer Corporate Events
Regulatory Filings and Compliance
Ubben-Linked Trust Buys €1.19 Million in Bayer Shares
Positive
Jul 1, 2026
Bayer disclosed a managers’ transaction in which the Jeffrey and Laura Ubben 2000 Trust, a person closely associated with supervisory board member Jeffrey Ubben, purchased Bayer shares on the Xetra trading platform. The trust executed numero...
Business Operations and StrategyRegulatory Filings and Compliance
Bayer Board Member Hartmann Buys Shares Under Management Commitment Program
Positive
Jun 9, 2026
Bayer disclosed a managers’ transaction involving Board of Management member Dr. Judith Hartmann, who purchased Bayer shares on June 5, 2026 via the Xetra trading platform. The purchases, made at a price of €35.84 per share and totalin...
Regulatory Filings and Compliance
Insider-Linked Investor Buys €1.69 Million in Bayer Shares
Positive
Jun 3, 2026
Bayer disclosed a managers’ transaction under EU Market Abuse Regulation, reporting that SF Investment One Pte Ltd., a person closely associated with supervisory board member Marcel Smits, purchased Bayer shares. The transaction involved Bay...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.